Cargando…

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy

BACKGROUND: Recombinant human endostatin (rh‐endostatin) plus standard chemotherapy in advanced non‐small cell lung cancer (NSCLC) patients has shown improved efficacy; however, it is unclear whether it is effective and safe when added to pemetrexed/cisplatin and used as maintenance therapy. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shengyu, Zuo, Lijie, He, Xiaohui, Pi, Jinping, Jin, Jun, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209785/ https://www.ncbi.nlm.nih.gov/pubmed/30152052 http://dx.doi.org/10.1111/1759-7714.12827

Ejemplares similares

Endostar (rh‐endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: An, Jihong, et al.
Publicado: (2018)

Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma
por: Li, Yuan, et al.
Publicado: (2019)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
por: Biaoxue, Rong, et al.
Publicado: (2012)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Yuan, Meng, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study
por: Xu, Hairong, et al.
Publicado: (2019)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
por: Ma, Xingqun, et al.
Publicado: (2012)

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
por: Pu, Xingxiang, et al.
Publicado: (2022)

Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer
por: Jia, Yitao, et al.
Publicado: (2011)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis
por: Wang, Cheng-Qiong, et al.
Publicado: (2021)

Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway
por: Xu, Xiaoming, et al.
Publicado: (2014)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

A new path for endostatin
por: Dove, Alan W.
Publicado: (2002)

Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study
por: Zhao, Jing, et al.
Publicado: (2022)

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer
por: Jia, Qianxin, et al.
Publicado: (2012)

Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model
por: Ge, Hong-yan, et al.
Publicado: (2011)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2014)

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
por: Garrido, Pilar, et al.
Publicado: (2017)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Endostatin expression in pancreatic tissue is modulated by elastase
por: Brammer, R D, et al.
Publicado: (2005)

Endostatin is a potential inhibitor of Wnt signaling
por: Hanai, Jun-ichi, et al.
Publicado: (2002)

Exercise increases endostatin in circulation of healthy volunteers
por: Gu, Jian-Wei, et al.
Publicado: (2004)

Endostatin inhibits bradykinin-induced cardiac contraction
por: YASUDA, Jumpei, et al.
Publicado: (2015)

Endostatin as a Biomarker of Basement Membrane Degradation
por: Sato, Yasufumi
Publicado: (2017)

Combined BRM270 and endostatin inhibit relapse of NSCLC while suppressing lung cancer stem cell proliferation induced by endostatin
por: Gu, Yan-hui, et al.
Publicado: (2021)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_t1ebuhll126o29i5a8gaee2geo